Status and phase
Conditions
Treatments
About
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis. This is a follow-up study to two Allergan sponsored studies (NCT00311376 and NCT00461292).
Full description
Botulinum toxin Type A 300U has been discontinued from the study. Patients remaining in the arm containing botulinum toxin Type A 300U will receive botulinum toxin Type A 200U moving forward. Also, the masking of the study is now open-label.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patient has participated in study 191622-515 or 191622-516 and the following criteria fulfilled:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
397 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal